Celgene receives positive CHMP opinion to extend REVLIMID(R) (Lenalidomide)
Celgene announced that the EMA's Committee for Medicinal Products for Human Use has adopted a positive opinion for continuous oral treatment with REVLIMID® in adult patients with previously untreated multiple myeloma who are not eligible for stem cell transplantation. December 19, 2014